Telli ML - Search Results

1

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.

2

First-line chemotherapy for metastatic breast cancer.

Telli ML, Carlson RW. Telli ML, et al. Clin Breast Cancer. 2009 Jun;9 Suppl 2:S66-72. doi: 10.3816/CBC.2009.s.007. Clin Breast Cancer. 2009. PMID: 19596645 Review.

3

Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls.

Gramatges MM, Telli ML, Balise R, Ford JM. Gramatges MM, et al. Among authors: telli ml. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):605-13. doi: 10.1158/1055-9965.EPI-09-0896. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20142254

4

Novel treatment approaches for triple-negative breast cancer.

Telli ML, Ford JM. Telli ML, et al. Clin Breast Cancer. 2010;10 Suppl 1:E16-22. doi: 10.3816/CBC.2010.s.003. Clin Breast Cancer. 2010. PMID: 20587403 Review.

5

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.

Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL. Telli ML, et al. Breast Cancer Res Treat. 2011 Jun;127(2):471-8. doi: 10.1007/s10549-010-1173-8. Epub 2010 Oct 19. Breast Cancer Res Treat. 2011. PMID: 20957431 Free PMC article.

6

PARP inhibitors in breast cancer.

Telli ML, Ford JM. Telli ML, et al. Clin Adv Hematol Oncol. 2010 Sep;8(9):629-35. Clin Adv Hematol Oncol. 2010. PMID: 21157412 Review.

7

Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.

Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, Telli M, Pochebit SM, Lypas G, Garber JE. Masciari S, et al. Breast Cancer Res Treat. 2012 Jun;133(3):1125-30. doi: 10.1007/s10549-012-1993-9. Epub 2012 Mar 4. Breast Cancer Res Treat. 2012. PMID: 22392042 Free PMC article.

8

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. Powell AA, et al. Among authors: telli ml. PLoS One. 2012;7(5):e33788. doi: 10.1371/journal.pone.0033788. Epub 2012 May 7. PLoS One. 2012. PMID: 22586443 Free PMC article.

9

Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome.

Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, Lebensohn A, Ford JM, Telli ML. Henry E, et al. Among authors: telli ml. J Natl Compr Canc Netw. 2012 Aug;10(8):939-42. doi: 10.6004/jnccn.2012.0097. J Natl Compr Canc Netw. 2012. PMID: 22878818

10

Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.

Golden DI, Lipson JA, Telli ML, Ford JM, Rubin DL. Golden DI, et al. Among authors: telli ml. J Am Med Inform Assoc. 2013 Nov-Dec;20(6):1059-66. doi: 10.1136/amiajnl-2012-001460. Epub 2013 Jun 19. J Am Med Inform Assoc. 2013. PMID: 23785100 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page